[Cost-Effectiveness Analysis of Maribavir in Patients with Post-Transplant Cytomegalovirus Infection or Disease that are Refractory or Resistant to Conventional Therapy]. Farmeconomia. Health Economics and Therapeutic Pathways, [S. l.], v. 24, n. 1, 2023. DOI: 10.7175/fe.v24i1.1548. Disponível em: https://journals.seedstm.com/index.php/FE/article/view/1548. Acesso em: 29 dec. 2025.